Roivant’s TYK2/JAK1 Inhibitor Lisraya Gains First Approval With Dermatomyositis
Roivant’s Priovant subsidiary gained US approval of brepocitinib in dermatomyositis. Priovant is pursuing additional indications for what is expected to be a blockbuster seller.
Scrip - August 28, 2026

CV Risk-Reduction Claim Likely To Strengthen Already Strong Mounjaro
The FDA approved the drug for lowering the risk of cardiovascular events, but it already has a wide lead over its rival, Novo Nordisk’s Ozempic.
Scrip - August 28, 2026

MFN Is Reshaping Pharma: More European Launch Delays, Headaches For Mid-Sized Pharma
Adapting to the challenges of Most Favored Nation pricing is a top priority in biopharma boardrooms, though the pricing gulf between the US and other developed nations looks impossible to bridge.
Scrip - August 28, 2026

ESC: Cytokinetics Confirms Strong Case For Myqorzo Label Expansion
The firm has revealed the extent of the win seen in the ACACIA-HCM study in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, a setting where Bristol Myers Squibb's rival cardiac myosin inhibitor Camzyos failed.
Scrip - August 28, 2026

US FDA Grants CorTec Second Breakthrough Device Designation For Brain-Computer Interface
CorTec said it received a second breakthrough device designation for its investigational Brain Interchange device for use to help people with non-progressive quadriplegia communicate. In April, the German BCI company received the same designation for use in stroke-related impairments.
Medtech Insight - August 30, 2026

Oregon EPR Law Survives Constitutional Test, Complicating Similar Legal Challenges
A federal court has upheld Oregon’s packaging EPR law, delivering a setback to industry groups challenging similar programs in other states.
HBW Insight - August 29, 2026

Apotex Addresses Tariffs As US-Canada Tensions Rise
Following the recent threat of US tariffs on imported generics from 2028, Apotex’s management has spoken about the uncertainty that remains surrounding the measure - but at the same time, says it is aligned with the Trump administration on its underlying goals.
Generics Bulletin - August 28, 2026

Takeda Patent Suit Puts Early Entyvio Biosimilar Launches Under Pressure
Takeda’s six-patent suit against Polpharma puts an early legal test in front of first-wave Entyvio biosimilar entrants, with both Polpharma and Alvotech targeting potential US approval in 2027.
Generics Bulletin - August 28, 2026

Mylan, Lannett Must Face Humana Jury On Generic Price-Fixing Claims
A US federal court has cleared Humana’s overarching conspiracy and multiple drug-specific claims against Mylan and Lannett for trial, setting up a September bellwether in the generic price-fixing multi-district litigation.
Generics Bulletin - August 28, 2026

Lupin Targets Bigger Global Role For Europe And Emerging Markets
In an exclusive interview, Lupin’s Thierry Volle describes how the firm is looking to roughly double its Europe and emerging markets business over five years, leaning on specialty care, selective biosimilars and complex generics.
Generics Bulletin - August 28, 2026

De-Risked Doesn’t Mean It’s A Safe Bet
Big pharma's late-stage M&A is not delivering: across deals since 2021, only 12 of the 33 involving a de-risked asset generated a multiple above 1.0x. In nearly two-thirds of cases the consensus forecast value of the late-stage assets acquired was less than the price paid for the company.
In Vivo - August 29, 2026